Zobrazeno 1 - 10
of 19
pro vyhledávání: '"James B. Geake"'
Autor:
Linda T. Viberg, Derek S. Sarovich, Timothy J. Kidd, James B. Geake, Scott C. Bell, Bart J. Currie, Erin P. Price
Publikováno v:
mBio, Vol 8, Iss 2 (2017)
ABSTRACT Cystic fibrosis (CF) is a genetic disorder characterized by progressive lung function decline. CF patients are at an increased risk of respiratory infections, including those by the environmental bacterium Burkholderia pseudomallei, the caus
Externí odkaz:
https://doaj.org/article/896cc757cfbf4f31ad9c761264b09b7b
Autor:
James B. Geake, Donald M. Ritchey, Jo Burke, Andrew Halliday, Richard Wood-Baker, Graeme Maguire
Publikováno v:
European Respiratory Review, Vol 23, Iss 131, Pp 145-147 (2014)
Externí odkaz:
https://doaj.org/article/44c8d8c2f13840f39590b1b1bbcb2c67
Autor:
James B. Geake, Graeme Maguire
Publikováno v:
Case Reports in Immunology, Vol 2012 (2012)
This is the first description that we are aware of describing the spontaneous resolution of an acute pulmonary vasculitis, possibly secondary to microscopic polyangiitis. Haemoptysis is a common symptom for patients presenting to primary and tertiary
Externí odkaz:
https://doaj.org/article/afca59f464434ff28c235950eefaa778
Publikováno v:
Respirology Case Reports, Vol 9, Iss 7, Pp n/a-n/a (2021)
Respirology Case Reports
Respirology Case Reports
Amyloidosis is an uncommon multisystem disease that can affect many organs. However, interstitial lung involvement is very rare. A 68‐year‐old man presented with long‐standing dyspnoea and productive cough. After extensive investigation, includ
Autor:
Peter O'Rourke, James B. Geake, Claire E. Wainwright, Scott C. Bell, David W. Reid, Emma Ballard
Publikováno v:
Internal medicine journalReferences. 50(2)
Cystic fibrosis (CF) is a common life-limiting genetic condition. As the disease progresses access to specialist tertiary multi-disciplinary care services may become necessary. For patients living in regional/remote Australia, accessing such services
Publikováno v:
Therapeutics and Clinical Risk Management. 12:1433-1444
Tiotropium bromide is a long-acting inhaled muscarinic antagonist used in patients with chronic respiratory disease. It has been available since 2002 as a single-dose dry powder formulation via the HandiHaler® dry powder inhaler (DPI) device, and si
Publikováno v:
Internal Medicine Journal. 45:395-401
Background: Beta-lactam antibiotic-related liver enzyme derangement can limit treatment options for infective exacerbations in cystic fibrosis (CF) bronchiectasis. Aim: To identify risk factors for elevated liver function tests (LFT) in CF patients r
Autor:
Scott C. Bell, James B. Geake, Timothy J. Kidd, Bart J. Currie, Derek S. Sarovich, Erin P. Price, Linda T. Viberg
Publikováno v:
mBio, Vol 8, Iss 2 (2017)
mBio, Vol 8, Iss 2, p e00356-17 (2017)
mBio
mBio, Vol 8, Iss 2, p e00356-17 (2017)
mBio
Cystic fibrosis (CF) is a genetic disorder characterized by progressive lung function decline. CF patients are at an increased risk of respiratory infections, including those by the environmental bacterium Burkholderia pseudomallei, the causative age
Autor:
Scott C. Bell, James B. Geake
Publikováno v:
Respirology. 23:797-798
Publikováno v:
Obstetric medicine. 7(4)
Over the previous 50 years survival of patients with cystic fibrosis has progressively increased. As a result of improvements in health care, increasing numbers of patients with cystic fibrosis are now considering starting families of their own. For